Loading…
Curtis Jacquot dba Pacific BioLogic Co. was cited for significant Current Good Manufacturing Practice (CGMP) violations under 21 CFR Part 111 discovered during a June 2023 inspection of their Concord, California dietary supplement manufacturing facility. The company's product labels and websites made disease claims (cure, mitigation, treatment, or prevention) that caused their dietary supplements to be classified as unapproved drugs under the Federal Food, Drug, and Cosmetic Act, and several products were misbranded for lacking adequate directions for use. The company's response to the FDA 483 inspection observations was deemed inadequate, as it only targeted partial corrections and referenced procedures and forms that were not provided for FDA review.